Washington Post - "A Cure for Cancer? This Big Data Startup Says It Can Deliver"
'Big data' is one of the most over-used buzzwords in the startup vernacular, and founders rarely have the goods to back it up. But Ayasdi, a startup, doesn't just talk the talk. Stanford researchers have been baking the complex algorithms behind Ayasdi for over a decade, with the goal of unlocking the hidden value in human genetic data. Dr. Eric Schadt, Director of the Institute for Genomics and Multiscale Biology at the Icahn School of Medicine at Mount Sinai, has a team of researchers using the technology to identify the genetic predispositions of many diseases, including cancer, which they hope will help them "glean new insights that will lead to breakthrough drug therapies." Mount Sinai is using Ayasdi to analyze the entire E. Coli genome sequence, which includes more than one million DNA variants. This will further our understanding of why some types of E. Coli develop resistance to antibiotics and how we can combat the spread of the bacteria. Learn more